SCHEDULE 13D/A: SR One Capital's Stake in Design Therapeutics Dips
Beneficial Ownership Update
SR One Capital reports a decrease in its beneficial ownership percentage of Design Therapeutics, Inc. common stock due to an increase in the total outstanding shares.
Summary
- SR One Capital Fund I Aggregator, LP, SR One Capital Partners I, LP, SR One Capital Management, LLC, and Simeon George, M.D. (collectively, the "Reporting Persons") have filed an Amendment No. 2 to their Schedule 13D.
- The amendment reports a decrease of more than 1% in the beneficial ownership percentage of Design Therapeutics, Inc. common stock held by the Reporting Persons.
- This decrease is attributed to an increase in the total number of Common Stock outstanding, not a sale by the Reporting Persons.
- As of March 9, 2026, the Reporting Persons collectively beneficially own approximately 10.6% to 10.7% of Design Therapeutics' common stock.
- The percentage is calculated based on 61,672,279 shares of Common Stock outstanding as of March 2, 2026, as reported by Design Therapeutics, Inc. in its Form 10-K.
- No transactions in Design Therapeutics common stock were effected by the Reporting Persons in the last 60 days.
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a slightly negative development for the reporting investors due to dilution, but it is an administrative update rather than a direct negative action by the investors themselves. The underlying reason for the increase in outstanding shares is not detailed here.
Positives
- The Reporting Persons have not sold any shares in the last 60 days, indicating continued holding of their investment.
Negatives
- The beneficial ownership percentage of the Reporting Persons has decreased by more than 1%, indicating dilution of their stake.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding Design Therapeutics, Inc.'s future performance or strategic direction.
Management Comments
- The filing does not contain notable quotes or paraphrased statements from company management of Design Therapeutics, Inc. The statements are from the reporting persons' attorney-in-fact regarding the filing itself.
Industry Context
StockSavvy.ai notes that a decrease in a significant investor's percentage ownership, even if due to dilution rather than divestment, can sometimes signal a company's capital-raising activities or other share issuances, which are common in the biotechnology sector for funding research and development.
Comparison to Industry Standards
- This filing is an update to beneficial ownership and does not contain information that allows for a direct comparison to industry-specific operational or financial benchmarks. It primarily reflects a change in the denominator of the ownership calculation.
Legal Proceedings
- None of the Reporting Persons have been convicted in a criminal proceeding during the past five years.
- None of the Reporting Persons have been a party to a civil proceeding ending in a judgment, decree, or final order enjoining future violations of, or prohibiting activities subject to, federal or state securities laws or finding any violation with respect to such laws during the past five years.
Related Party Transactions
- The filing does not disclose any related party dealings beyond the organizational structure of the Reporting Persons themselves.
Stakeholder Impact
- Shareholders: Existing shareholders of Design Therapeutics, Inc. (including the Reporting Persons) experience dilution of their percentage ownership due to the increase in outstanding shares.
- Company (Design Therapeutics, Inc.): The increase in outstanding shares likely indicates a successful capital raise or other issuance, which could provide additional funding for operations or strategic initiatives.
Next Steps
- The filing does not explicitly mention any future actions, events, or milestones for Design Therapeutics, Inc. or the Reporting Persons beyond the administrative filing requirements.
Key Dates
| Date | Description |
|---|---|
| 2021-04-09 | Original Schedule 13D filing date. |
| 2022-12-12 | Date of execution of the Limited Power of Attorney by Simeon George and related entities. |
| 2022-12-22 | Amendment No. 1 to Schedule 13D filing date. |
| 2026-03-02 | Date as of which 61,672,279 shares of Common Stock were reported outstanding by the Issuer in its Form 10-K. |
| 2026-03-09 | Date of event requiring the filing of this statement (increase in outstanding shares leading to >1% decrease in beneficial ownership percentage). |
| 2026-03-09 | Date of Issuer's Form 10-K filing with the SEC. |
| 2026-03-11 | Execution date of the Agreement regarding filing of joint Schedule 13D and the current Amendment No. 2. |
Recommendation
holdWhile the filing indicates dilution for existing shareholders, it is an administrative update reflecting an increase in outstanding shares, not a divestment by a major investor. The underlying reason for the share increase (e.g., capital raise for R&D) is not detailed here, preventing a definitive 'buy' or 'sell' recommendation based solely on this filing. Investors should 'hold' and await further details on the purpose and terms of the share issuance from Design Therapeutics, Inc. itself.
Keywords
Design Therapeutics, SR One Capital, Schedule 13D/A, Beneficial Ownership, Common Stock, Equity Stake, SEC Filing, Investment Fund, Biotechnology, Dilution
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.